Our Firm is representing plaintiffs in Xarelto lawsuits, and we are pleased that the multidistrict litigation is moving forward. The establishment of these protocols will allow discovery in these cases to move forward efficiently.
New York, New York (PRWEB) June 09, 2015
Discovery is moving forward in hundreds of federal Xarelto lawsuits (http://www.xareltolawsuit2015.com/ ) that have been consolidated in the U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order issued on June 4th, the Court has established protocols governing the treatment of all privileged or work product materials in the proceeding. Among other things, the Order sets forth procedures for the production of privilege logs, as well as a process by which receiving parties may challenge a redaction or claim of privilege or work product.
“Our Firm is representing plaintiffs in Xarelto lawsuits, and we are pleased that the multidistrict litigation is moving forward. The establishment of these protocols will allow discovery in these cases to move forward efficiently,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.
Court documents indicate that more than 430 Xarelto lawsuits have been filed in the Eastern District of Louisiana, all of which accuse the drug’s manufacturers of failing to warn patients about its alleged association with dangerous internal bleeding and other serious complications. Among other things, plaintiffs allege that sale of Xarelto were driven by marketing claims that positioned the drug as a superior alternative to warfarin, a medication that has been on the market for decades. The lawsuits point out that while hemorrhaging associated with warfarin can be stopped via the administration of vitamin K, there is currently no approved agent to reverse Xarelto bleeding. Plaintiffs also claim that the manufacturers’ contention that Xarelto patients do not require regular blood monitoring is questionable, and assert that individuals treated with the anticoagulant would benefit from such monitoring.
According to court records, Xarelto was initially approved by the U.S. Food & Drug Administration in 2011, and is now indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP